Skip to Main Content

Browse issues

Volume 211, Issue 3, March 2023

Editors’ Choice

Liwei Fang and others
Clinical and Experimental Immunology, Volume 211, Issue 3, March 2023, Pages 193–207, https://doi.org/10.1093/cei/uxad017

The N-terminal domain of Three Prime Repair Exonuclease 1 (TREX1) is catalytically active and can degrade dsDNA or ssDNA in the cytosol, whereas the C-terminal domain is primarily involved in protein localization. TREX1 deficiency induces cytosolic DNA accumulation as well as activation of the cGAS-STING-IFN signaling pathway, which results in tissue inflammation and autoimmune diseases. Furthermore, TREX1 expression in cancer immunity can be adaptively regulated to promote tumor proliferation, making it a promising therapeutic target.

Review

Cornelia M Weyand and others
Clinical and Experimental Immunology, Volume 211, Issue 3, March 2023, Pages 208–223, https://doi.org/10.1093/cei/uxac107

The concept of how autoimmunity occurs in rheumatoid arthritis is changing. Besides autoantigen recognition, the responsiveness of T cells and macrophages is determined by their bioenergetics and their biosynthetic commitment. Mitochondria are emerging as critical drivers of autoimmunity by controlling production of energy and metabolites and by regulating the communication of subcellular organelles.

Autoimmunity / Autoimmune Disease

Julie Vandewalle and others
Clinical and Experimental Immunology, Volume 211, Issue 3, March 2023, Pages 224–232, https://doi.org/10.1093/cei/uxad002

The impact of HLA-DQ2/DQ8, the main genetic risk factor for accelerating progression from 1 to multiple autoantibodies, largely depended on CTLA4 status in the Belgian cohort.

Teresina Laragione and others
Clinical and Experimental Immunology, Volume 211, Issue 3, March 2023, Pages 233–238, https://doi.org/10.1093/cei/uxac124

We compared a TRPV2 agonist with etanercept. Both achieved similar effects in suppressing arthritis and reducing joint damage. The combination of both agents was superior than the monotherapies.

Immune Regulation

Abby D Ivey and others
Clinical and Experimental Immunology, Volume 211, Issue 3, March 2023, Pages 239–247, https://doi.org/10.1093/cei/uxad005

Proposed mechanisms of neutrophil extracellular trap (NET) inhibition by CQ and HCQ. Chloroquine (CQ) and hydroxychloroquine (HCQ) inhibit NET formation through direct inhibition of PAD4, which is responsible for unwinding and release of DNA from neutrophils. When considered with regard to the established function of CQ/HCQ in autophagy inhibition and of the role of autophagy in NETs, we suggest two independent mechanisms for NET inhibition by these drugs, through blockade of autophagy or inhibition of PAD4.

Infection / Infectious Disease

Octavio A Gonzalez and others
Clinical and Experimental Immunology, Volume 211, Issue 3, March 2023, Pages 248–268, https://doi.org/10.1093/cei/uxac122

Macrophage polarization is a critical component of tissue homeostasis, disease processes, and resolution. This report describes features of macrophage polarization using a nonhuman primate model of experimental periodontitis. The results show clear features of macrophage phenotype in health, disease, and resolution and identify alterations with age.

Vaccine Development

C Green and others
Clinical and Experimental Immunology, Volume 211, Issue 3, March 2023, Pages 269–279, https://doi.org/10.1093/cei/uxad003

PanAd3 vaccination of healthy adults induces type-1 interferon and humoral immune responses.

Merryn Voysey and others
Clinical and Experimental Immunology, Volume 211, Issue 3, March 2023, Pages 280–287, https://doi.org/10.1093/cei/uxad013

Total spike-specific IgG antibody responses after two doses of ChAdOx1 nCov-19 (AZD1222) persist well for 1 year. Modelling suggesting titres are well maintained for at least 2 years. Therefore, two doses of ChAdOx1 nCov-19 will likely have a positive impact against serious disease and hospitalization.

Inflammation / Inflammatory Disease

Huimei Wu and others
Clinical and Experimental Immunology, Volume 211, Issue 3, March 2023, Pages 288–300, https://doi.org/10.1093/cei/uxad004

Epicutaneous application of mannan mixed with incomplete Freund’s adjuvant induced clinical symptoms of plaque psoriasis in inbred mice. Although certain similarities and differences exist in the involvement of neutrophils, macrophages, dendritic cells, Vγ4 T cells, and pro-inflammatory cytokines between mannan- and imiquimod-induced psoriasis-like inflammation, former model was more severe with a better relapsing disease feature and treatment response. In addition, mannan-induced psoriasis is relatively easy to induce, economical and less harmful to mice with an increased possibility to develop a chronic psoriasis model in mice with repeated exposures.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close